GlassScriptPhysician profile
Nicholas August Werth
NPI 1306590765
$3,072.52
in general payments reported to CMS, 2019-2025
32 companies · $605 in 2025
The $605 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $161 · 2023: $594 · 2024: $1,713 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,911.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $382.63 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Medtronic, INC. | $354.40 | 2023-2025 | Inceptiv, Kyphon Express II Kyphopak Tray, Intellis Adaptivestim |
| Amgen INC. | $340.38 | 2022-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $301.81 | 2023-2025 | |
| Novo Nordisk INC | $264.79 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Globus Medical, INC. | $157.11 | 2025 | Senza |
| Angiodynamics, INC. | $135.29 | 2023 | Auryon Laser System 100-120 Vac |
| Abbott Laboratories | $128.88 | 2024-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $119.73 | 2024-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $115.60 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $85.62 | 2023-2025 | |
| Glaxosmithkline, LLC. | $83.44 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.13 | 2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.75 | 2023-2025 | Xifaxan, Trulance |
| Baxter Healthcare | $57.70 | 2024 | Hillrom - Carnation Ambulatory Monitor |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $45.15 | 2023-2024 | Inspire |
| Boston Scientific Corporation | $34.32 | 2024-2025 | General - Tachy |
| Azurity Pharmaceuticals, INC. | $34.11 | 2024-2025 | |
| Nalu Medical, INC. | $32.91 | 2023 | Nalu Neurostimulation System |
| Kowa Pharmaceuticals America, INC. | $32.85 | 2024-2025 | Zoryve |
| Astellas Pharma US INC | $27.80 | 2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $27.25 | 2022 | |
| Grt US Holding, INC. | $23.42 | 2022 | |
| Axsome Therapeutics, INC. | $21.24 | 2024 | Auvelity |
| Dexcom, INC. | $19.87 | 2025 | Dexcom G6 Transmitter |
| Nevro Corp. | $17.99 | 2022 | |
| Aimmune Therapeutics, INC. | $17.92 | 2024 | |
| Pfizer INC. | $17.88 | 2024 | |
| Radius Health, INC. | $16.72 | 2025 | Tymlos |
| Lucid Diagnostics INC. | $16.47 | 2022 | |
| Merck Sharp & Dohme LLC | $15.65 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Exact Sciences Corporation | $12.71 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Werth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.